18th International Conference of the Research Institute of Ophthalmology

RIO 2026

22 -23 JANUARY 2026

ROYAL MAXIM PALACE KEMPINSKI, CAIRO

Efficacy and Safety of LipiFlow® versus Intense Pulsed Light for Meibomian Gland Dysfunction: A Systematic Review and Meta-analysis

Presenter: Raghad Saleh Alajlan
Senior Medical Student, College of Medicine, Imam Mohammad Ibn Saud Islamic University, Riyadh, Saudi Arabia

Principal Investigator: Dr. Tariq Alasbali, Consultant Ophthalmologist, IMSIU

Background & Clinical Context

Meibomian gland dysfunction (MGD) : Primary cause of evaporative Dry Eye Disease (DED); marked by gland obstruction and unstable tear film.

Prevalence: Affects 30–70% globally; underdiagnosed, undertreated.

Clinical Impact: Leads to discomfort, visual disturbance, and reduced quality of life.

Treatment Gap: Traditional options (compresses, hygiene) yield temporary benefit.

Emerging Therapies: LipiFlow® and IPL (Intense Pulsed Light) are device-based treatments .

Study Rationale & Objective

Although LipiFlow® and IPL are used for MGD, direct comparisons are limited.

This study aims to

- Compare the efficacy of LipiFlow® and IPL in improving TBUT, MGS, and OSDI.
- Assess safety and patient-reported satisfaction.

Method

. **Study design:** Systematic review & meta-analysis

.**Study guidelines:** followed PRISMA 2020

.**Databases**: PubMed, CENTRAL, Google Scholar (2012–2023)

:**Eligibility criteria**

.**Inclusion:** English RCTs; adults with MGD; LipiFlow® vs IPL

.**Exclusion:** Non-RCTs, reviews, case reports, non-English

RIO 2026

Study Selection & Outcomes

Study Selection: 13 studies; >1,200 participants; multicenter, international.

:Outcomes

Primary: Tear Break-Up Time (TBUT), Meibomian Gland Score (MGS), Ocular Surface Disease-
.Index (OSDI)

.**Secondary:** tear osmolarity, safety, patient satisfaction-

.**Bias Assessment**: Cochrane RoB 2 tool used

RIO 2026

LipiFlow® : Clinical Efficacy & Safety Outcomes

- **TBUT**: Improvement up to +2.0 seconds in individual trials (e.g., Lane et al.), but pooled MD: 0.68s (95% CI: −0.22 to 1.59; I^2 = 92.2%) → Not statistically significant.
- **MGS**: Strong improvement in expressibility (e.g., from 6.3 to 16.7).
- **OSDI**: Significant symptom relief (e.g., reduction from 38.1 to 24.3).
- **Tear Osmolarity**: Mild reduction in osmolarity; variable reporting across studies.
- **Patient Satisfaction**: Generally high, especially in short-term symptom improvement.
- **Safety**: highly favorable; no serious adverse events; transient pressure discomfort most common.



Figure 1. Effect of LipiFlow® on TBUT in RCTs

RIO 2026

IPL: Clinical Efficacy & Safety Outcomes

- **TBUT**: Consistently improved across trials. Pooled MD: +1.85s (95% CI: 0.98–2.73); statistically significant.
- **MGS**: 193% increase in gland scores (Yan et al.); enhanced lipid secretion.
- **OSDI**: Sustained improvement, especially in studies with IPL + MGX (Arita et al.; Toyos et al.).
- **Tear Osmolarity**: Improved in trials using combined IPL + MGX.
- **Patient Satisfaction**: High across all time points, particularly with longer follow-up.
- **Safety**: Excellent; transient, mild erythema or warmth reported, resolving without intervention.



Figure 2. Effect of IPL on TBUT in RCTs

RIO 2026

Comparative Analysis Table

Outcomes	LipiFlow®	IPL
Tear Break-Up Time (TBUT)	+0.68 sec (NS, pooled)	+1.85 sec ($p<0.001$)
Meibomian Gland Score (MGS)	↑ Significant improvement (More clear secretions)	↑ Significant improvement (better gland expressibility)
Ocular Surface Disease Index (OSDI)	↑ Symptom relief (reduced OSDI scores)	↑ Symptom relief (reduced OSDI scores)
Tear Osmolarity	Limited effect, no consistent reduction	Improved osmolarity in several trials
Patient Satisfaction	High satisfaction	High satisfaction
Safety & Tolerability	Well-tolerated, mild transient discomfort	Well-tolerated, mild transient erythema

Table 1. Comparative safety and effectiveness of LipiFlow® and IPL in MGD

Limitations & Future Directions

:Limitations

.Substantial **heterogeneity** ($I^2 > 90\%$ in TBUT)

.**Short follow-up** (mostly ≤12 weeks)-

.Many **small-sample RCTs** (<50 participants)-

.Some trials lacked **blinding** or complete reporting-

.**Geographic clustering** (Asia-dominant studies)-

:Future Research

- Long-term, multicenter head-to-head RCTs.
- Cost-effectiveness analysis.
- Stratification by MGD subtypes.

RIO 2026

Conclusion

.Both LipiFlow® and IPL are **safe, effective, and evidence-supported** treatments for MGD

.Both therapies shows **substantial and sustained improvements** in MGD

.Clinical choice should be **individualized**

.Combination or sequential use may provide **synergistic benefits**

.**Need for** large-scale, multicenter, standardized RCTs with longer follow-up

RIO 2026

References

RIO 2026